Costs and effectiveness of fingolimod versus alemtuzumab in the treatment of highly active relapsing-remitting multiple sclerosis in the UK: re-treatment, discount, and disutility

References

• Nylander A, Hafler DA. Multiple sclerosis. J Clin Invest 2012;122:1180-8
   PubMed Web of Science ®Google Scholar
• Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46:907-11
   PubMed Web of Science ®Google Scholar
• Tremlett H, Zhu F, Petkau J, et al. Natural, innate improvements in multiple sclerosis disability. Mult Scler 2012;18:1412-21
   PubMed Web of Science ®Google Scholar
• Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52
   PubMed Web of Science ®Google Scholar
• Oreja-Guevara C. Overview of magnetic resonance imaging for management of relapsing-remitting multiple sclerosis in everyday practice. Eur J Neurol 2015;22(Suppl2):22-7
   Web of Science ®Google Scholar
• Kamm CP, Uitdehaag BM, Polman CH. Multiple sclerosis: current knowledge and future outlook. Eur Neurol 2014;72:132-41
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. GILENYA 0.5 mg hard capsules. Summary of Product Characteristics. 2015. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002202/WC500104528.pdf. Accessed March 29, 2016
   Google Scholar
• European Medicines Agency. TYSABRI 300 mg concentrate for solution for infusion. Summary of Product Characteristics. 2016. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000603/WC500044686.pdf. Accessed April 30, 2016
   Google Scholar
• National Institute for Health and Care Excellence. Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis (TA254). 2012. https://www.nice.org.uk/guidance/ta254. Accessed November 8, 2016
   Google Scholar
• European Medicines Agency. LEMTRADA 12 mg concentrate for solution for infusion. Summary of Product Characteristics. 2014. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/003718/WC500150521.pdf. Accessed May 16, 2016
   Google Scholar
• Coles AJ, Arnold DL, Cohen JA, et al. Patients with active RRMS and an inadequate response to prior therapy demonstrate durable improvements in relapse and disability following treatment with alemtuzumab: 5-year follow-up of the CARE-MS II study. Presented at the 68th Annual Meeting of the American Academy of Neurology, April 15–21, 2016, Vancouver (BC), Canada
   Google Scholar
• Tuohy O, Costelloe L, Hill-Cawthorne G, et al. Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy. J Neurol Neurosurg Psychiatry 2015;86:208-15
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Alemtuzumab for treating relapsing–remitting multiple sclerosis (TA312), 2014. https://www.nice.org.uk/guidance/ta312. Accessed November 8, 2016
   Google Scholar
• McCrone P, Heslin M, Knapp M, et al. Multiple sclerosis in the UK: service use, costs, quality of life and disability. Pharmacoeconomics 2008;26:847-60
   PubMed Web of Science ®Google Scholar
• Allen F, Montgomery S, Maruszczak M, et al. Convergence yet continued complexity: a systematic review and critique of health economic models of relapsing-remitting multiple sclerosis in the United Kingdom. Value Health 2015;18:925-38
   PubMed Web of Science ®Google Scholar
• Montgomery S, Kusel J, Allen F, et al. Paucity and inconsistency: a systematic review and critique of budget impact analyses of disease-modifying therapies for multiple sclerosis in the UK and the implications for policy in the UK. Appl Health Econ Health Policy 2016;14:545–558
   PubMed Web of Science ®Google Scholar
• Maruszczak MJ, Montgomery SM, Griffiths MJ, et al. Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England. J Med Econ 2015;18:874-85
   PubMed Web of Science ®Google Scholar
• Caro JJ, Moller J. Advantages and disadvantages of discrete-event simulation for health economic analyses. Expert Rev Pharmacoecon Outcomes Res 2016;16:327-9
   PubMed Web of Science ®Google Scholar
• Roberts M, Russell LB, Paltiel AD, et al. Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force–2. Value Health 2012;15:804-11
   PubMed Web of Science ®Google Scholar
• Kusel J, Maruszczak M, Adlard N. Cost-utility of fingolimod compared with dimethyl fumarate (Dmf) in highly active relapsing remitting multiple sclerosis (Rrms) in England: comparison of a Markov and discrete event simulation model. Value Health 2015;18:A759
   PubMed Web of Science ®Google Scholar
• Montgomery SM, Maruszczak MJ, Slater D, et al. A discrete event simulation to model the cost-utility of fingolimod and natalizumab in rapidly evolving severe relapsing-remitting multiple sclerosis in the UK. J Med Econ 2017;20:474-82
   PubMed Web of Science ®Google Scholar
• Kappos L, Radue EW, O’Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362:387-401
   PubMed Web of Science ®Google Scholar
• Calabresi PA, Radue EW, Goodin D, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol 2014;13:545-56
   PubMed Web of Science ®Google Scholar
• Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362:402-15
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Guide to the methods of technology appraisal; 2013. https://www.nice.org.uk/process/pmg9/. Accessed November 8, 2016
   Google Scholar
• Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989;112(Pt1):133-46
   Web of Science ®Google Scholar
• Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012;380:1829-39
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Daclizumab for treating relapsing-remitting multiple sclerosis (TA441); 2017. https://www.nice.org.uk/guidance/ta441. Accessed May 19, 2017
   Google Scholar
• National Institute for Health and Care Excellence. Dimethyl fumarate for treating relapsing–remitting multiple sclerosis (TA320); 2014. https://www.nice.org.uk/guidance/ta320. Accessed November 8, 2016
   Google Scholar
• Derfuss T, Bergvall NK, Sfikas N, et al. Efficacy of fingolimod in patients with highly active relapsing-remitting multiple sclerosis. Curr Med Res Opin 2015;31:1687-91
   PubMed Web of Science ®Google Scholar
• Tramacere I, Del Giovane C, Salanti G, et al. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. Cochrane Database Syst Rev 2015:CD011381
   PubMed Web of Science ®Google Scholar
• Havrdov E. Disease-free outcomes with alemtuzumab: 3-year follow-up of the CARE-MS studies. Presented at the 6th Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis, September 10–13, 2014, Boston (MA).
   Google Scholar
• National Institute for Health and Care Excellence. Apremilast for treating active psoriatic arthritis (TA433); 2017. https://www.nice.org.uk/guidance/ta433. Accessed May 19, 2017
   Google Scholar
• European Medicines Agency. Gilenya: EPAR - Assessment Report; 2011. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002202/WC500104529.pdf. Accessed November 8, 2016
   Google Scholar
• Havrdová E, Kappos L, Cohen J, et al. Clinical and magnetic resonance imaging outcomes in subgroups of patients with highly active relapsing–remitting multiple sclerosis treated with fingolimod (FTY720): results from the FREEDOMS and TRANSFORMS phase 3 studies. Presented at the 5th Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis, October 19–22, 2011, Amsterdam, The Netherlands.
   Google Scholar
• Garrison LP Jr, Neumann PJ, Erickson P, et al. Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report. Value Health 2007;10:326-35
   PubMed Web of Science ®Google Scholar
• Palace J, Bregenzer T, Tremlett H, et al. UK multiple sclerosis risk-sharing scheme: a new natural history dataset and an improved Markov model. BMJ Open 2014;4:e004073
   PubMed Web of Science ®Google Scholar